NovoBiome launches to develop microbiome-based therapies

By The Science Advisory Board staff writers

May 4, 2021 -- NovoBiome has been launched as a drug discovery company focused on the development of live biotherapeutic products targeting the microbiome-gut-liver axis.

The company is building ex vivo research and discovery platforms, leveraging expertise in microbiology and artificial intelligence, to analyze the symbiotic relationship between the microbiota and the human intestine. NovoSift is designed to mimic human intestinal physiology and unlock new insights into disease pathophysiology and reveal novel drug targets, compounds, and live biotherapeutic drug candidates.

NovoBiome's first drug candidate, ADC-001, for nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis, is made of an anti-inflammatory bacterium with demonstrated in vitro and preclinical potency. The company aims to begin human clinical trials by 2022-2023.

New intestine chips promote precision in preclinical models
A new intestine-on-a-chip platform enables researchers to model host-microbiome relationships to gain new insights into the mechanisms of infectious disease...
Microbes shape antibodies prior to infection
Genetic analysis of antibodies reveals how microbes in the intestines impact overall B-cell populations and humoral responses to pathogens. The research...

Copyright © 2021

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter